GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort CardioFlow Medtech Corp (HKSE:02160) » Definitions » Debt-to-EBITDA

MicroPort CardioFlow Medtech (HKSE:02160) Debt-to-EBITDA : -0.12 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is MicroPort CardioFlow Medtech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MicroPort CardioFlow Medtech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$31.2 Mil. MicroPort CardioFlow Medtech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$45.8 Mil. MicroPort CardioFlow Medtech's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-626.0 Mil. MicroPort CardioFlow Medtech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MicroPort CardioFlow Medtech's Debt-to-EBITDA or its related term are showing as below:

HKSE:02160' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.64   Med: -0.3   Max: -0.07
Current: -0.15

During the past 6 years, the highest Debt-to-EBITDA Ratio of MicroPort CardioFlow Medtech was -0.07. The lowest was -1.64. And the median was -0.30.

HKSE:02160's Debt-to-EBITDA is ranked worse than
100% of 437 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs HKSE:02160: -0.15

MicroPort CardioFlow Medtech Debt-to-EBITDA Historical Data

The historical data trend for MicroPort CardioFlow Medtech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort CardioFlow Medtech Debt-to-EBITDA Chart

MicroPort CardioFlow Medtech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.34 -0.07 -1.06 -0.26 -0.18

MicroPort CardioFlow Medtech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.57 -0.48 -0.15 -0.24 -0.12

Competitive Comparison of MicroPort CardioFlow Medtech's Debt-to-EBITDA

For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MicroPort CardioFlow Medtech's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MicroPort CardioFlow Medtech's Debt-to-EBITDA falls into.



MicroPort CardioFlow Medtech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MicroPort CardioFlow Medtech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(31.247 + 45.842) / -422.252
=-0.18

MicroPort CardioFlow Medtech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(31.247 + 45.842) / -625.952
=-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


MicroPort CardioFlow Medtech  (HKSE:02160) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


MicroPort CardioFlow Medtech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort CardioFlow Medtech (HKSE:02160) Business Description

Traded in Other Exchanges
Address
No. 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.
Executives
China Renaissance Holdings Limited 2201 Interest of corporation controlled by you
Hua Jie Tian Jin Yi Liao Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Hua Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Tian Jin Hua Jie Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hua Qing Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Microport Scientific Corporation 2201 Interest of corporation controlled by you
Shanghai Microport Limited 2101 Beneficial owner
China International Capital Corporation Limited 2201 Interest of corporation controlled by you
Cicc Capital Management Co., Ltd. 2201 Interest of corporation controlled by you
Cicc Kangrui I (ningbo) Equity Investment Limited Partners (limited Partnership) 2101 Beneficial owner
Cicc Kangzhi (ningbo) Equity Investment Management Co., Ltd. 2201 Interest of corporation controlled by you

MicroPort CardioFlow Medtech (HKSE:02160) Headlines

No Headlines